{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:00:22Z","timestamp":1787238022770,"version":"build-2736575974"},"reference-count":54,"publisher":"SAGE Publications","issue":"7-8","license":[{"start":{"date-parts":[[2002,7,1]],"date-time":"2002-07-01T00:00:00Z","timestamp":1025481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2002,7]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Anecdotal reports and case studies have described psychological disturbances and aggressive behavior in some men taking sildenafil. In the course of assisting the defense in a trial in which a man was alleged to have committed rape and in which sildenafil was implicated, a mechanistic hypothesis was formulated by the first author for central nervous system (CNS) adverse effects associated with the use of sildenafil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To examine whether there was any scientific information available to suggest a possible mechanism for or an association between exposure to sildenafil and aggressive behavior.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>The scientific literature on sildenafil, nitric oxide (NO), and the NO\u2014cyclic-guanosine monophosphate (cyclic-GMP) signaling pathway was reviewed. Adverse event reports that referenced sildenafil and were filed with the Food and Drug Administration Adverse Event Reporting System between January 4, 1998, and February 21, 2001, also were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Published studies reported that sildenafil crosses the blood\u2014brain barrier, that it exerts various biochemical and physiologic effects in the brain, and that it affects information processing. Other published reports indicated that phosphodiesterase type 5 (PDE-5), NO synthase, and guanylyl cyclase are present at highest activities in areas of the brain responsible for behavior, sexual drive, and emotion, and that NO modulates aggression and sexual behavior in male mice. In addition, 274 adverse event reports designated sildenafil as the primary suspect of various neurologic disturbances, amnesia, and aggressive behavior.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION:<\/jats:title>\n                    <jats:p>Evidence has been presented for an association between sildenafil and various CNS adverse effects, including aggressive behavior. Whether sildenafil causes these effects by inhibiting PDE-5 in the brain, accumulating cyclic-GMP, decreasing NO, and affecting cell\u2014cell signaling and modulation of aggressive behavior requires further investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>It is recommended that, before prescribing sildenafil for erectile dysfunction, clinicians should caution their patients and their partners on the possibility of neurologic, emotional, or psychological disturbances; amnesia or loss of consciousness; or aggressive behavior.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1a402","type":"journal-article","created":{"date-parts":[[2003,6,4]],"date-time":"2003-06-04T16:21:48Z","timestamp":1054743708000},"page":"1129-1134","source":"Crossref","is-referenced-by-count":73,"title":["Neurologic, Psychological, and Aggressive Disturbances with Sildenafil"],"prefix":"10.1177","volume":"36","author":[{"given":"Harry A","family":"Milman","sequence":"first","affiliation":[{"name":"Harry A Milman PhD, President, , Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne B","family":"Arnold","sequence":"additional","affiliation":[{"name":"Suzanne B Arnold MILS, Director of Research, MTI\/NICOM, Inc., Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2002,7,1]]},"reference":[{"key":"bibr1-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805143382001"},{"key":"bibr2-aph.1A402","first-page":"19","volume":"102","author":"Shabsigh R","year":"1999","journal-title":"Int J Clin Pract"},{"key":"bibr3-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1177\/014556139807700916"},{"key":"bibr4-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(99)00079-X"},{"key":"bibr5-aph.1A402","volume-title":"Viagra","year":"2002"},{"key":"bibr6-aph.1A402","volume-title":"Pfizer announces second-quarter net income up 31 percent to $1.890 billion and diluted EPS up 30 percent to $0.30, both from continuing operations excluding certain significant items and merger-related costs","year":"2001"},{"key":"bibr7-aph.1A402","first-page":"3","volume":"102","author":"Osterloh I","year":"1999","journal-title":"Int J Clin Pract"},{"key":"bibr8-aph.1A402","first-page":"6","volume":"102","author":"Young J","year":"1999","journal-title":"Int J Clin Pract"},{"key":"bibr9-aph.1A402","first-page":"8","volume":"102","author":"Goldstein I","year":"1999","journal-title":"Int J Clin Pract"},{"key":"bibr10-aph.1A402","first-page":"10","volume":"102","author":"Feldman R","year":"1999","journal-title":"Int J Clin Pract"},{"key":"bibr11-aph.1A402","first-page":"27","volume":"102","author":"Hartmann U","year":"1999","journal-title":"Int J Clin Pract"},{"key":"bibr12-aph.1A402","first-page":"32","volume":"102","author":"Eardley I","year":"1999","journal-title":"Int J Clin Pract"},{"key":"bibr13-aph.1A402","first-page":"1753","volume":"24","year":"2000","journal-title":"AHFS drug information"},{"key":"bibr14-aph.1A402","volume-title":"Viagra (sildenafil citrate) tablets","year":"1999"},{"key":"bibr15-aph.1A402","unstructured":"Drug information for the health care professional. Sildenafil. USP drug information 2000. 20th ed. 2000;1: 2772\u20135."},{"key":"bibr16-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1080\/00926239908403988"},{"key":"bibr17-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.51.5.674"},{"key":"bibr18-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00610-X"},{"key":"bibr19-aph.1A402","unstructured":"Igoe RE. Viagra killer gets 18 years. The Kansas City Star. December 21, 1999:B1."},{"key":"bibr20-aph.1A402","unstructured":"Ben-Tal D. Tel Aviv court rejects Viagra defense in rape trial. The Jerusalem Post. March 24, 1999:5."},{"key":"bibr21-aph.1A402","volume-title":"FDA Adverse Event Reporting System (AERS), Freedom of Information Report. Adverse Reaction Reports \u2014 Viagra, for the period January 4, 1998, through February 21, 2001","author":"US Food and Drug Administration","year":"2001"},{"key":"bibr22-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.25.3068"},{"key":"bibr23-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1007\/PL00007092"},{"key":"bibr24-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1007\/BF03401818"},{"key":"bibr25-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1038\/378383a0"},{"key":"bibr26-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.47.1.219"},{"key":"bibr27-aph.1A402","volume-title":"Code of Federal Regulations. Title 21 \u2014 Food and Drugs","volume":"5","author":"US Food and Drug Administration","year":"2001"},{"key":"bibr28-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.13.5159"},{"key":"bibr29-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(91)81123-P"},{"key":"bibr30-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(98)00171-7"},{"key":"bibr31-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1007\/s002210000602"},{"key":"bibr32-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ph.57.030195.003343"},{"key":"bibr33-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1997.00206.x"},{"key":"bibr34-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(98)00158-1"},{"key":"bibr35-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(93)90021-T"},{"key":"bibr36-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200101220-00013"},{"key":"bibr37-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(92)90290-N"},{"key":"bibr38-aph.1A402","first-page":"9","volume":"1","author":"Dawson TM","year":"1996","journal-title":"Mol Psychiatry"},{"key":"bibr39-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(00)01996-2"},{"key":"bibr40-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(97)00688-4"},{"key":"bibr41-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.98.3.1277"},{"key":"bibr42-aph.1A402","first-page":"163","volume":"39","author":"Waldman GMP","year":"1987","journal-title":"Pharmacol Rev"},{"key":"bibr43-aph.1A402","first-page":"305","volume":"169","author":"Kantak KM","year":"1984","journal-title":"Prog Clin Biol Res"},{"key":"bibr44-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(81)80003-2"},{"key":"bibr45-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)75965-1"},{"key":"bibr46-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1993.2595"},{"key":"bibr47-aph.1A402","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200023010-00001"},{"key":"bibr48-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7184.669"},{"key":"bibr49-aph.1A402","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jama.1962.03050260028005","volume":"180","author":"Taussig HB","year":"1962","journal-title":"JAMA"},{"key":"bibr50-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00705-1"},{"key":"bibr51-aph.1A402","first-page":"A553","volume":"35","author":"Azarbal B","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"bibr52-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.5.590-JMN0202-2-1"},{"issue":"12","key":"bibr53-aph.1A402","first-page":"5","volume":"10","year":"2000","journal-title":"Harv Heart Lett"},{"key":"bibr54-aph.1A402","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/14.8.2045"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1A402","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1A402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:05:52Z","timestamp":1777374352000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1A402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":54,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["10.1345\/aph.1A402"],"URL":"https:\/\/doi.org\/10.1345\/aph.1a402","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7]]}}}